Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.46 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.46 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29727448 | 1.00 | MALT1 (0.52) | MALT1IDO1GAAPDK2TPSAB1 | |
| SCHEMBL25719625 | 0.92 | GAA (0.58) | MALT1IDO1GAAPDK2TPSAB1 | |
| SCHEMBL12143602 | 0.92 | MALT1 (0.50) | MALT1IDO1GAAPDK2TPSAB1 | |
| SCHEMBL31314288 | 0.92 | MALT1 (0.50) | MALT1IDO1GAAPDK2TPSAB1 | |
| SCHEMBL8752938 | 0.91 | TPSAB1 (0.51) | MALT1IDO1GAATPSAB1TPSD1 | |
| SCHEMBL17264137 | 0.90 | TPSAB1 (0.53) | MALT1GAATPSAB1TPSD1TPSG1 | |
| SCHEMBL15344850 | 0.90 | GAA (0.44) | MALT1IDO1GAAPDK2TPSAB1 | |
| SCHEMBL6298459 | 0.88 | MALT1 (0.49) | MALT1IDO1GAAPDK2TPSAB1 | |
| SCHEMBL12143071 | 0.86 | GAA (0.54) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL18756433 | 0.86 | GAA (0.41) | MALT1IDO1GAAPDK2TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177460-A1 | HMOX1 INDUCERS | Astellas Engineered Small Molecules US, Incorporated | 2022-06-09 | — | — | US | disclosed |
| EP-3154997-B9 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| US-10766888-B1 | HMOX1 inducers | MITOBRIDGE INC. (US) | 2020-09-08 | — | — | US | disclosed |
| EP-3154997-B1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2020-02-19 | — | — | EP | disclosed |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-05-07 | — | — | US | disclosed |
| US-20180186814-A1 | TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL | SHIONOGI & CO., LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180186814-A1 | TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL | SHIONOGI & CO., LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| WO-2018072697-A1 | OXADIAZOLE RING-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, COMPOSITE, AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2018-04-26 | — | — | WO | disclosed |
| US-9884817-B2 | Auristatin derivatives and conjugates thereof | NOVARTIS AG (CH) | 2018-02-06 | — | — | US | disclosed |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. | 2004-09-16 | — | — | US | disclosed |
| US-20040176325-A1 | P38 MAP kinase inhibitors comprising indazole derivatives; antiinflammatory and antiproliferative agents; autoimmune, bone, and neurodegenerative disorders; viricides, infections | ARRAY BIOPHARMA INC. | 2004-09-09 | — | — | US | disclosed |
| EP-0629617-B1 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INT BV (NL) | 1998-04-29 | — | — | EP | disclosed |
| US-5741912-A | DIAGNOSIS, THERAPY | BRACCO INTERNATIONAL B.V. | 1998-04-21 | — | — | US | disclosed |
| US-5665329-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-09-09 | — | — | US | disclosed |
| US-5656254-A | Polyaza heteroatom-bearing ligands and metal complexes thereof for imaging or radiotherapy | BRACCO INTERNATIONAL B.V. | 1997-08-12 | — | — | US | disclosed |
| US-5627286-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-05-06 | — | — | US | disclosed |
| US-5608110-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-03-04 | — | — | US | disclosed |
| EP-0629617-A1 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO International B.V. (NL) | 1994-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176325-A1 | P38 MAP kinase inhibitors comprising indazole derivatives; antiinflammatory and antiproliferative agents; autoimmune, bone, and neurodegenerative disorders; viricides, infections | MAPK1, MAPK3, MAP3K1 | MALT1 450/4885IDO1 123/4885GAA 1749/4885 |
| US-10766888-B1 | HMOX1 inducers | HMOX1, HMOX2, HMBS | MALT1 1235/4885IDO1 85/4885GAA 2202/4885 |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | MALT1 3089/4885IDO1 2578/4885GAA 2590/4885 |
| US-20180186814-A1 | TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL | SULT1E1, ABCC5, ABCC4 | MALT1 1544/4885IDO1 3593/4885GAA 3025/4885 |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, MKI67, NGLY1 | MALT1 324/4885IDO1 2211/4885GAA 512/4885 |
| US-20220177460-A1 | HMOX1 INDUCERS | HMOX1, HMOX2, HMBS | MALT1 1077/4885IDO1 74/4885GAA 2123/4885 |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | MALT1 3089/4885IDO1 2578/4885GAA 2590/4885 |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | CD47, MKI67, NGLY1 | MALT1 324/4885IDO1 2211/4885GAA 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.